Literature DB >> 9495698

Increased incidence of serendipitously discovered renal cell carcinoma.

M Jayson1, H Sanders.   

Abstract

OBJECTIVES: To determine the proportion of renal cell carcinomas that are discovered serendipitously, and to compare the tumor stages of symptomatic versus incidental tumors.
METHODS: We reviewed the charts of 131 consecutive patients who had a nephrectomy for renal cell carcinoma between 1989 and 1993. We excluded from the numerator any patients with abdominal pain or mass related to the tumor, even if the diagnosis of renal cell carcinoma had not been entertained before imaging studies.
RESULTS: Eighty (61%) of 131 patients were diagnosed with renal cell tumors in the absence of flank pain, flank mass, or hematuria. Of these 131 patients, 31 (24%) presented with gross hematuria, 13 (10%) with flank pain, and 10 (8%) with flank or abdominal mass. Only 1 patient presented with the classic triad of flank pain, flank mass, and gross hematuria. Eighty-five percent of asymptomatic tumors were Stage I or II, and 77% of symptomatic tumors were Stage I or II.
CONCLUSIONS: The great majority of renal cell tumors are found incidentally. The tumor stage is the same in the incidentally discovered cases as it is in the symptomatic cases.

Entities:  

Mesh:

Year:  1998        PMID: 9495698     DOI: 10.1016/s0090-4295(97)00506-2

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  169 in total

Review 1.  Should there be a size limit for elective nephron-sparing surgery?

Authors:  Kent G Krejci; Bradley C Leibovich
Journal:  Curr Urol Rep       Date:  2003-02       Impact factor: 3.092

Review 2.  Management of locally recurrent kidney cancer.

Authors:  Eric A Singer; Gennady Bratslavsky
Journal:  Curr Urol Rep       Date:  2010-02       Impact factor: 3.092

Review 3.  Image-guided percutaneous ablation of renal tumors: outcomes, technique, and application in urologic practice.

Authors:  Adam C Mues; Jaime Landman
Journal:  Curr Urol Rep       Date:  2010-02       Impact factor: 3.092

Review 4.  Extracorporeal stereotactic radiosurgery for small renal masses.

Authors:  Gino J Vricella; Nicholas A Boncher; Lee E Ponsky
Journal:  Curr Urol Rep       Date:  2010-02       Impact factor: 3.092

5.  Renal mass biopsy to guide treatment decisions for small incidental renal tumors: a cost-effectiveness analysis.

Authors:  Pari V Pandharipande; Debra A Gervais; Rebecca I Hartman; Mukesh G Harisinghani; Adam S Feldman; Peter R Mueller; G Scott Gazelle
Journal:  Radiology       Date:  2010-09       Impact factor: 11.105

Review 6.  Management of incidental renal masses: Time to consider contrast-enhanced ultrasonography.

Authors:  Francesca Di Vece; Paola Tombesi; Francesca Ermili; Sergio Sartori
Journal:  Ultrasound       Date:  2016-01-14

7.  Prospective comparison of use of contrast-enhanced ultrasound and contrast-enhanced computed tomography in the Bosniak classification of complex renal cysts.

Authors:  Matthew Ragel; Anbu Nedumaran; Jolanta Makowska-Webb
Journal:  Ultrasound       Date:  2016-01-24

8.  Diagnostic Performance and Interreader Agreement of a Standardized MR Imaging Approach in the Prediction of Small Renal Mass Histology.

Authors:  Fernando U Kay; Noah E Canvasser; Yin Xi; Daniella F Pinho; Daniel N Costa; Alberto Diaz de Leon; Gaurav Khatri; John R Leyendecker; Takeshi Yokoo; Aaron H Lay; Nicholas Kavoussi; Ersin Koseoglu; Jeffrey A Cadeddu; Ivan Pedrosa
Journal:  Radiology       Date:  2018-02-01       Impact factor: 11.105

9.  Disparities in the treatment of patients with IL-2 for metastatic renal cell carcinoma.

Authors:  Christopher S Saigal; Christopher M Deibert; Julie Lai; Matthias Schonlau
Journal:  Urol Oncol       Date:  2008-12-12       Impact factor: 3.498

10.  Solid tumors after chemotherapy or surgery for testicular nonseminoma: a population-based study.

Authors:  Chunkit Fung; Sophie D Fossa; Michael T Milano; Jan Oldenburg; Lois B Travis
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.